Husni ME, et al. - In this Phase 3, randomized, placebo-controlled trial (GO-VIBRANT), investigators assessed the effectiveness and safety of intravenous golimumab in subjects with active psoriatic arthritis (PsA). They noted the following achievements at week 52: 76.8% of cases in the golimumab group and 77.0% in the placebo-crossover group achieved an ACR20 response, 58.1% and 53.6%, respectively, an ACR50 response, and 38.6% and 33.9%, respectively, achieved an ACR70 response. They also reported mean change from baseline in the total vdH-S score of -0.5 in the golimumab group and 0.8 in the placebo-crossover group. They identified no new safety signals for IV golimumab and suggested sustained improvements in joint and skin disease in candidates with PsA.